US 10488416
Targeting breast cancer therapy based on stromal subtypes and CD146 composition
granted A61KA61K31/138A61K31/517
Quick answer
US patent 10488416 (Targeting breast cancer therapy based on stromal subtypes and CD146 composition) held by The Regents of the University of Colorado, a Body Corporate expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of Colorado, a Body Corporate
- Grant date
- Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/138, A61K31/517, A61K31/5377, A61K31/565